Foghorn Therapeutics (FHTX) Return on Capital Employed (2020 - 2026)
Foghorn Therapeutics' (FHTX) quarterly Return on Capital Employed came in at 58.36% in Q1 2026, down 967.0% year-on-year from 6.73% in Q1 2025, and up 4.21% quarter-over-quarter from 60.93% in Q4 2025.
Foghorn Therapeutics (FHTX) Return on Capital Employed (2020 - 2026) Analysis & Trends
Foghorn Therapeutics' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 58.36% for Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 967.0% year-over-year to 58.36% in Q1 2026; TTM through Mar 2026 was 58.36%, a 967.0% decrease from a year earlier, with the FY2025 full-year figure at 47.65%, down 54.0% from the prior year.
- Return on Capital Employed advanced to 58.36% in Q1 2026 per FHTX's latest filing, from 60.93% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 23.13% in Q1 2022 and bottomed at 66.29% in Q3 2025.
- The 5-year median for Return on Capital Employed is 41.89% (2023), against an average of 43.4%.
- Across the five-year window, Return on Capital Employed jumped 2344 bps in 2022 and sank 2649 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 32.16% in 2022, then tumbled by 39 bps to 44.73% in 2023, then declined by 0 bps to 44.8% in 2024, then sank by 36 bps to 60.93% in 2025, then rose by 4 bps to 58.36% in 2026.
- Per Business Quant, the three latest FHTX Return on Capital Employed figures stand at 58.36% (Q1 2026), 60.93% (Q4 2025), and 66.29% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Foghorn Therapeutics | 352.57 Mn | 263.66 Mn | - | -58.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.36% |
| Dec 31, 2025 | -60.93% |
| Sep 30, 2025 | -66.29% |
| Jun 30, 2025 | -55.79% |
| Mar 31, 2025 | -48.69% |
| Dec 31, 2024 | -44.80% |
| Sep 30, 2024 | -39.80% |
| Jun 30, 2024 | -40.41% |
| Mar 31, 2024 | -47.06% |
| Dec 31, 2023 | -44.73% |
| Sep 30, 2023 | -41.65% |
| Jun 30, 2023 | -41.89% |
| Mar 31, 2023 | -36.82% |
| Dec 31, 2022 | -32.16% |
| Sep 30, 2022 | -29.04% |
| Jun 30, 2022 | -26.22% |
| Mar 31, 2022 | -23.13% |
| Dec 31, 2021 | -33.11% |
| Sep 30, 2021 | -52.49% |
| Jun 30, 2021 | -42.24% |